Toad Venom Could Be the Next Depression Blockbuster
A molecule squeezed from a desert toad is now the subject of a two-company pharmaceutical race, and Wall Street is already pricing in an approval that does not exist yet. The business story is who…
Read the full articleYou might also wanna read
The Big Pharma Psychedelic Buyout Spree Has Begun
The Big Pharma Psychedelic Buyout Spree Has Begun Submitted by QTR's Fringe Finance Massive validation for psychedelics…not as drugs, but as
Final psychedelics guidance suggests FDA is 'receptive' to helping companies succeed
The agency’s finalized recommendations for clinical testing of psychedelic compounds for mental health could pave the way for companies like
Synthetic Psilocybin Shows Strong Results in Treatment-Resistant Depression Trials
Regulators are now mulling the results of the late-stage trial
economist.com·4mo ago
US biotechs turn secretive as they fear competition from rising Chinese industry
US biotechs turn tight-lipped on gene targets and pipelines as China's fast-follower threat intensifies, 20+ founders and investors tell End
endpoints.news·7d ago
The debate about whether the NHS should use magic mushrooms to treat depression
Many clinical trials to test the use of psychedelic medicines for conditions such as depression have been underway since 2022 - with surpris
The future of US psychedelic medicine is carved out by the FDA
The US Food and Drug Administration (FDA) has issued its first comprehensive guidance on how psychedelic drugs should best be studied in cli
The future of US psychedelic medicine is carved out by the FDA
The US Food and Drug Administration (FDA) has issued its first comprehensive guidance on how psychedelic drugs should best be studied in cli
Comments
Sign in to join the conversation.
No comments yet. Be the first.